SDS Optic #news: more milestones and the development of inPROBE

April 19, 2022

The first quarter of 2022 is behind us. As we announced during our debut on the NewConnect market, this year is full of significant events. We are consistently pursuing all of the Company's planned goals and are pleased to announce the achievement of further milestones in the inPROBE project – a fiber-optic probe for diagnosing HER2-positive breast cancer. So, what exactly has been happening in our Company?

Achievement of a milestone in the implementation of pilot production of fiber optic biosensors

Shortly after SDS Optic's debut on the NewConnect market, we published a report in the ESPI system announcing the completion of the first stage of implementing pilot production of optoelectronic components for fiber-optic biosensors, designed for use in inPROBE microsensors. This stage included the design process, ordering, and purchase of dedicated, customized fixed assets (production devices and machinery) worth PLN 2.4 million.To achieve this goal, our company secured funds from the issuance of Series D shares, with the purchases identified in the Information Document as one of the key objectives to be completed following the company's listing on NewConnect. This marks a significant step toward achieving production independence in manufacturing and preparing the optoelectronic (photonic) components of fiber-optic biosensors (microsensors). The creation of a professional production line, along with the expansion of our R&D team in the field of photonics, will enable us to produce up to 50,000 proprietary biosensors annually. In the next stages of development, we plan to: launch and calibrate production processes, hire new R&D team members, conduct validation and certification of the planned production, and prepare certified process and production documentation.

SDS Optic S.A., as one of the 20 most innovative companies in the EU, will represent the European Pavilion at the BIO 2022 conference in San Diego, US

At the end of March, we received the news that our company had been recognized as one of the 20 most technologically advanced firms in the EU. SDS Optic S.A., along with the other selected companies, will represent the EU in a special pavilion at BIO 2022—the largest event of its kind in the US. The conference brings together the most influential players in the biotechnology and pharmaceutical industries.

From June 13 to 16, 2022 during the conference, we plan to engage in an intensive exchange of knowledge with experts from the BioTech and Pharma industries. This time will also be filled with networking opportunities with potential future partners. We believe that our technology can significantly enhance the quality of services and products across many sectors related to medicine. We are strongly committed to promoting our inPROBE technology for real-time drug delivery monitoring. The BIO 2022 event is an excellent opportunity to do so. The conference is packed with interesting lectures and presentations that not only keep us up to date with the latest developments in medicine and pharmacology, but also greatly boost our creativity.

SDS Optic's first investor chat

On April 12, SDS Optic held its first investor chat. Our Leadership Team shared the most important and interesting events from the company's life. The company was represented by: Marcin Staniszewski, CEO, founder, and shareholder, Magdalena Staniszewska, Director of Research and Development, founder, and shareholder, and Mateusz Sagan, Chief Operating Officer and Director of Business Development, and shareholder. Investors had the opportunity to receive first-hand information about our inPROBE optical fiber microprobe for minimally invasive diagnostics of cancer, infectious and fungal diseases, and real-time drug delivery monitoring. In the webinar, you will learn: what our development strategy is; how cancer diagnostics are performed today; how the inPROBE microprobe will change this process in the future; what business model the company is implementing related to commercialization; and what goals and plans SDS Optic has for the next 1; explain our industrial property protection policy; introduce the current technical infrastructure of the company; and discuss how the development process of the production background will unfold.

The signing of the annex to the grant agreement under the SME Instrument Horizon 2020 program

Since its debut on the NewConnect market, an annex has also been signed to the agreement with the European Commission regarding the Company’s grant of €3,985,000 under the SME Instrument Horizon2020 program. This funding supports R&D efforts, clinical trials, and the certification of a diagnostic microsensor device for HER2+ breast cancer, developed under the inPROBE brand. The European Commission has thus confirmed the validity of using the remaining portion of the funding awarded in 2017. SDS Optic S.A. still has €985,000 at its disposal. These funds will be used to carry out the ongoing clinical trials, cover salaries for the R&D team as well as administrative and management staff, and support certification activities, communication, and commercialization of the inPROBE technology. The annex was signed to align the project schedule under the SME Instrument Horizon2020 program with the work schedule of SDS Optic S.A.